# Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

> **NCT03741530** · NA · COMPLETED · sponsor: **Xijing Hospital** · enrollment: 220 (actual)

## Conditions studied

- Intracerebral Hemorrhage

## Interventions

- **DRUG:** Glibenclamide Tablets
- **OTHER:** Standard management for ICH

## Key facts

- **NCT ID:** NCT03741530
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-15
- **Primary completion:** 2020-09-23
- **Final completion:** 2020-09-23
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2022-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03741530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03741530, "Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03741530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*